Tyra Biosciences (NASDAQ:TYRA) Research Coverage Started at Piper Sandler

Piper Sandler began coverage on shares of Tyra Biosciences (NASDAQ:TYRA) in a report released on Thursday morning, MarketBeat reports. The brokerage issued an overweight rating and a $33.00 price objective on the stock.

Several other research firms also recently commented on TYRA. Oppenheimer reduced their price objective on Tyra Biosciences from $28.00 to $25.00 and set an outperform rating for the company in a research note on Thursday, August 8th. Wedbush restated an outperform rating and set a $28.00 price target on shares of Tyra Biosciences in a research note on Thursday, August 8th. Finally, HC Wainwright reiterated a buy rating and issued a $23.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Tyra Biosciences presently has a consensus rating of Moderate Buy and a consensus price target of $24.80.

Tyra Biosciences Price Performance

TYRA stock opened at $21.74 on Thursday. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -12.94 and a beta of 1.02. The company has a fifty day moving average price of $19.23 and a 200 day moving average price of $18.14. Tyra Biosciences has a 12 month low of $10.38 and a 12 month high of $24.25.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. As a group, analysts anticipate that Tyra Biosciences will post -1.52 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In other news, COO Daniel Bensen sold 3,502 shares of Tyra Biosciences stock in a transaction on Monday, June 10th. The stock was sold at an average price of $20.00, for a total transaction of $70,040.00. Following the completion of the transaction, the chief operating officer now owns 427,981 shares of the company’s stock, valued at approximately $8,559,620. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 15.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. raised its position in shares of Tyra Biosciences by 1,244.2% in the fourth quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock valued at $29,000 after buying an additional 1,916 shares during the last quarter. Victory Capital Management Inc. lifted its position in Tyra Biosciences by 53.4% during the fourth quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock worth $696,000 after buying an additional 17,490 shares during the period. AJOVista LLC purchased a new stake in Tyra Biosciences in the 4th quarter valued at about $59,000. Kynam Capital Management LP acquired a new position in shares of Tyra Biosciences during the 4th quarter valued at about $4,712,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Tyra Biosciences by 8.8% during the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after acquiring an additional 8,324 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.